Healthcare · NSE/BSE: SHILPAMED
Shilpa Medicare Limited
Pharmaceuticals
Market Cap ₹0.11L Cr
Verdict: Average
Quality Scores
Multi-Bagger
71/100
Compounder Quality
59/100
Management Credibility
65/100
Governance
72/100
Cash Flow Quality
40/100
AI Summary
Shilpa Medicare is a specialized pharmaceutical player with a strong foothold in the oncology API and formulation segments. Over the last decade, the company has transitioned from a pure-play API manufacturer to a vertically integrated player with expanding capabilities in biologics and novel drug delivery systems. While revenue growth has been steady at an 8% 10-year CAGR, profitability has faced significant headwinds due to heavy R&D spending and regulatory inspections at key facilities. Recent performance shows a sharp recovery, with trailing twelve-month (TTM) profit growth exceeding 165%…
Top Opportunities
- Leading API manufacturer in Oncology niche
- Strong historical presence in regulated markets
- Robust revenue growth in TTM (20%)
Top Risks
- Persistently negative Free Cash Flow for 10 years
- Constant equity dilution (Equity capital up)
- High inventory days (291-427 range)
Latest report: Read the annual report summary →
Unlock the full report
Full sections, financial charts, AI chat and PDF export are available with Premium.